Tempus AI (NASDAQ:TEM) Shares Gap Up – Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $50.77, but opened at $52.82. Tempus AI shares last traded at $55.66, with a volume of 2,764,572 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Loop Capital reduced their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America increased their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Tempus AI Stock Performance

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s fifty day moving average is $44.18 and its 200-day moving average is $48.18.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 82,056 shares of Tempus AI stock in a transaction on Friday, January 31st. The shares were sold at an average price of $58.21, for a total value of $4,776,479.76. Following the completion of the transaction, the chief executive officer now owns 5,532,987 shares of the company’s stock, valued at $322,075,173.27. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director David R. Epstein sold 620 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,037,702 shares of company stock valued at $89,449,651.

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares during the last quarter. ARK Investment Management LLC boosted its stake in Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after purchasing an additional 1,855,459 shares during the period. NEA Management Company LLC grew its position in Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after purchasing an additional 813,169 shares during the last quarter. Millennium Management LLC bought a new position in Tempus AI in the 2nd quarter worth about $8,067,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Tempus AI in the second quarter valued at approximately $5,250,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.